Serum Cystatin C for Early Detection of Acute Kidney Injury After Primary Percutaneous Coronary Intervention

NCT06459362 | Not Yet Recruiting

• 1 other identifier: SSAS
• Study Type: observational
• Target: 45
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims to evaluate whether the serum levels of Cystatin C (CysC) can be used as early biomarkers for the identification of patients who are prone to AKI after cardiac interventional surgeries as primary percutaneous coronary intervention (PCI)

Conditions

Acute Kidney Injury

Outcome Measures

Primary Outcomes (1)

• prevention and screening for early detection of acute kidney injury

  using serum levels of Cystatin C (CysC) as early biomarkers for the identification of patients who are prone to AKI after cardiac inteventional surgeries as primary percutaneous coronary intervention (PCI)

  2 years

Interventions

Serum cystatin C DIAGNOSTIC_TEST

Diagnostic test for detection of acute kidney injury

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patient with typical chest pain and treated by primary percutaneous intervention

You may qualify if:

• Age ≥ 18 years.
• Patient with absolute increase in serum creatinine ≥0.3 mg/dl (≥26.4 μmol/l) or with percentage increase in serum creatinine ≥50% (1.5-fold from baseline)
• Patient with reduction in urine output (documented oliguria \< 0.5 ml/kg/hour for \> 6 hours)
• Patient with typical chest pain, ECG changes, Echocardiogram positive finding

You may not qualify if:

• History of nephrectomy
• patient with renal transplantation
• patient with renal replacement therapy initiated before admission
• patient with chronic kidney disease
• patient on regular haemodialysis
• patient known to be diabetic

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Central Study Contacts

shrouk sayed ahmed

CONTACT

+201123232632; shrookabozaid@gmail.com

shrouk sayed ahmed

CONTACT

01123232632; shrookabozaid@gmail.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Demonstrator

Study Record Dates

• First Submitted: May 31, 2024
• First Posted: June 14, 2024
• Study Start: July 1, 2024
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2027
• Last Updated: June 14, 2024

Record last verified: 2024-06

Data Sharing

• IPD Sharing: Will not share